Page last updated: 2024-11-12
Erinacine C
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
erinacine C: from filamentous fungus Hericium erinaceus with potential to treat Alzheimer's disease; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10252378 |
| CHEBI ID | 187640 |
| SCHEMBL ID | 21003630 |
Synonyms (9)
| Synonym |
|---|
| erinacine c |
| (1r,2r,5r,10r,14r,16r,17s,18r,21s)-13-(hydroxymethyl)-2,5-dimethyl-8-propan-2-yl-15,20,22-trioxapentacyclo[12.8.0.02,10.05,9.016,21]docosa-8,12-diene-17,18-diol |
| CHEBI:187640 |
| SCHEMBL21003630 |
| DTXSID901318487 |
| erinacin c |
| beta-d-xylopyranose, 1,2-o-[(3ar,5ar,6r,7r,10ar)-2,3,3a,4,5,5a,6,7,10,10a-decahydro-8-(hydroxymethyl)-3a,5a-dimethyl-1-(1-methylethyl)cyclohept[e]indene-6,7-diyl]- |
| 1,2-o-[(3ar,5ar,6r,7r,10ar)-2,3,3a,4,5,5a,6,7,10,10a-decahydro-8-(hydroxymethyl)-3a,5a-dimethyl-1-(1-methylethyl)cyclohept[e]indene-6,7-diyl]-beta-d-xylopyranose |
| RR9WB4ATX2 |
Research Excerpts
Overview
Erinacine C is a cyathane scaffold-based secondary metabolite. It is naturally produced by the filamentous fungus Hericium erinaceus. It has a high potential to treat nervous diseases such as Alzheimer's disease.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Erinacine C is a cyathane scaffold-based secondary metabolite, which is naturally produced by the filamentous fungus Hericium erinaceus and has a high potential to treat nervous diseases such as Alzheimer's disease. " | ( Erinacine C: A novel approach to produce the secondary metabolite by submerged cultivation of Hericium erinaceus. Merz, J; Schembecker, G; Wolters, N, 2015) | 3.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||